A targeted IL-15 fusion protein with potent anti-tumor activity

References

• Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y. Cytokines in cancer immunity and immunotherapy. Immunol Rev 2004; 202:275-93; PMID:15546400; http://dx.doi.org/10.1111/j.0105-2896.2004.00199.x
   PubMed Web of Science ®Google Scholar
• Fehniger TA, Cooper MA, Caligiuri MA. Interleukin-2 and interleukin-15: immunotherapy for cancer. Cytokine Growth Factor Rev 2002; 13:169-83; PMID:11900992; http://dx.doi.org/10.1016/S1359-6101(01)00021-1
   PubMed Web of Science ®Google Scholar
• Dafne M. Targeted cancer immunotherapy: mimicking physiological trans-presentation of IL-15. Oncoimmunology 2012; 1:1213-4; PMID:23170284; http://dx.doi.org/10.4161/onci.20824
   PubMedGoogle Scholar
• Dubois S, Mariner J, Waldmann TA, Tagaya Y. IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity 2002; 17:537-47; PMID:12433361; http://dx.doi.org/10.1016/S1074-7613(02)00429-6
   PubMed Web of Science ®Google Scholar
• Rochman Y, Spolski R, Leonard WJ. New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol 2009; 9:480-90; PMID:19543225; http://dx.doi.org/10.1038/nri2580
   PubMed Web of Science ®Google Scholar
• Kermer V, Baum V, Hornig N, Kontermann RE, Muller D. An antibody fusion protein for cancer immunotherapy mimicking IL-15 trans-presentation at the tumor site. Mol Cancer Ther 2012; 11:1279-88; PMID:22491823; http://dx.doi.org/10.1158/1535-7163.MCT-12-0019
   PubMed Web of Science ®Google Scholar
• Cheever MA. Twelve immunotherapy drugs that could cure cancers. Immunol Rev 2008; 222:357-68; PMID:18364014; http://dx.doi.org/10.1111/j.1600-065X.2008.00604.x
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Carrasquillo JA, Paik CH, Waldmann TA, Tagaya Y. Differences of biodistribution, pharmacokinetics, and tumor targeting between interleukins 2 and 15. Cancer Res 2000; 60:3577-83; PMID:10910071
   PubMed Web of Science ®Google Scholar
• Bessard A, Sole V, Bouchaud G, Quemener A, Jacques Y. High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor α fusion protein, in metastatic melanoma and colorectal cancer. Mol Cancer Ther 2009; 8:2736-45; PMID:19723883; http://dx.doi.org/10.1158/1535-7163.MCT-09-0275
   PubMed Web of Science ®Google Scholar
• Rubinstein MP, Kovar M, Purton JF, Cho JH, Boyman O, Surh CD, Sprent J. Converting IL-15 to a superagonist by binding to soluble IL-15R{α}. Proc Natl Acad Sci USA 2006; 103:9166-71; PMID:16757567; http://dx.doi.org/10.1073/pnas.0600240103
   PubMed Web of Science ®Google Scholar
• Stoklasek TA, Schluns KS, Lefrançois L. Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo. J Immunol 2006; 177:6072-80; PMID:17056533; http://dx.doi.org/10.4049/jimmunol.177.9.6072
   PubMed Web of Science ®Google Scholar
• Dubois S, Patel HJ, Zhang M, Waldmann TA, Muller JR. Preassociation of IL-15 with IL-15R α-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action. J Immunol 2008; 180:2099-106; PMID:18250415; http://dx.doi.org/10.4049/jimmunol.180.4.2099
   PubMed Web of Science ®Google Scholar
• Kukita T, Arima N, Matsushita K, Arimura K, Ohtsubo H, Sakaki Y, Fujiwara H, Ozaki A, Matsumoto T, Tei C. Autocrine and/or paracrine growth of adult T-cell leukaemia tumour cells by interleukin 15. Br J Haematol 2002; 119:467-74; PMID:12406087; http://dx.doi.org/10.1046/j.1365-2141.2002.03813.x
   PubMed Web of Science ®Google Scholar
• Yu YL, Wei CW, Chen YL, Chen MH, Yiang GT. Immunotherapy of breast cancer by single delivery with rAAV2-mediated interleukin-15 expression. Int J Oncol 2010; 36:365-70; PMID:20043070; http://dx.doi.org/10.3892/ijo_00000603
   PubMed Web of Science ®Google Scholar
• Vera M, Razquin N, Prieto J, Melero I, Fortes P, Gonzalez-Aseguinolaza G. Intratumoral injection of dendritic cells transduced by an SV40-based vector expressing interleukin-15 induces curative immunity mediated by CD8+ T lymphocytes and NK cells. Mol Ther 2005; 12:950-9; PMID:15921960; http://dx.doi.org/10.1016/j.ymthe.2005.03.030
   PubMed Web of Science ®Google Scholar
• Kaspar M, Trachsel E, Neri D. The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis. Cancer Res 2007; 67:4940-8; PMID:17510424; http://dx.doi.org/10.1158/0008-5472.CAN-07-0283
   PubMed Web of Science ®Google Scholar
• Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007; 7:715-25; PMID:17703228; http://dx.doi.org/10.1038/nri2155
   PubMed Web of Science ®Google Scholar
• Czajkowsky DM, Hu J, Shao Z, Pleass RJ. Fc-fusion proteins: new developments and future perspectives. EMBO Mol Med 2012; 4:1015-28; PMID:22837174; http://dx.doi.org/10.1002/emmm.201201379
   PubMed Web of Science ®Google Scholar
• Kontermann RE. Antibody-cytokine fusion proteins. Arch Biochem Biophys 2012; 526:194-205; PMID:22445675; http://dx.doi.org/10.1016/j.abb.2012.03.001
   PubMed Web of Science ®Google Scholar
• Aguzzi MS, Fortugno P, Giampietri C, Ragone G, Capogrossi MC, Facchiano A. Intracellular targets of RGDS peptide in melanoma cells. Mol Cancer 2010; 9:84; PMID:20412563; http://dx.doi.org/10.1186/1476-4598-9-84
   PubMed Web of Science ®Google Scholar
• Gao H, Xiong Y, Zhang S, Yang Z, Cao S, Jiang X. RGD and interleukin-13 peptide functionalized nanoparticles for enhanced glioblastoma cells and neovasculature dual targeting delivery and elevated tumor penetration. Mol Pharm 2014; 11:1042-52; PMID:24521297; http://dx.doi.org/10.1021/mp400751g
   PubMed Web of Science ®Google Scholar
• Chen K, Chen X. Integrin targeted delivery of chemotherapeutics. Theranostics 2011; 1:189-200; PMID:21547159; http://dx.doi.org/10.7150/thno/v01p0189
   PubMed Web of Science ®Google Scholar
• Danhier F, Le Breton A, Preat V. RGD-based strategies to target α(v) β(3) integrin in cancer therapy and diagnosis. Mol Pharm 2012; 9:2961-73; PMID:22967287; http://dx.doi.org/10.1021/mp3002733
   PubMed Web of Science ®Google Scholar
• Zhu X, Marcus WD, Xu W, Lee HI, Han K, Egan JO, Yovandich JL, Rhode PR, Wong HC. Novel human interleukin-15 agonists. J Immunol 2009; 183:3598-607; PMID:19710453; http://dx.doi.org/10.4049/jimmunol.0901244
   PubMed Web of Science ®Google Scholar
• Xiao K, Li Y, Lee JS, Gonik AM, Dong T, Fung G, Sanchez E, Xing L, Cheng HR, Luo J, et al. “OA02” peptide facilitates the precise targeting of paclitaxel-loaded micellar nanoparticles to ovarian cancer in vivo. Cancer Res 2012; 72:2100-10; PMID:22396491; http://dx.doi.org/10.1158/0008-5472.CAN-11-3883
   PubMed Web of Science ®Google Scholar
• Mortier E, Woo T, Advincula R, Gozalo S, Ma A. IL-15Ralpha chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation. J Exp Med 2008; 205:1213-25; PMID:18458113; http://dx.doi.org/10.1084/jem.20071913
   PubMed Web of Science ®Google Scholar
• Bouchaud G, Garrigue-Antar L, Sole V, Quemener A, Boublik Y, Mortier E, Perdreau H, Jacques Y, Plet A. The exon-3-encoded domain of IL-15ralpha contributes to IL-15 high-affinity binding and is crucial for the IL-15 antagonistic effect of soluble IL-15Ralpha. J Mol Biol 2008; 382:1-12; PMID:18656487; http://dx.doi.org/10.1016/j.jmb.2008.07.019
   PubMed Web of Science ®Google Scholar
• Wu Z, Xu Y. IL-15R α-IgG1-Fc enhances IL-2 and IL-15 anti-tumor action through NK and CD8+ T cells proliferation and activation. J Mol Cell Biol 2010; 2:217-22; PMID:20671116; http://dx.doi.org/10.1093/jmcb/mjq012
   PubMed Web of Science ®Google Scholar